Table 3.
Ongoing phase 3 or 4, currently recruiting randomized clinical trials of JAK inhibitors.
| Drug | Title | Design/NCT | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Baricitinib | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection (COV-BARRIER) | Double-blinded placebo-controlled RCT | NCT04421027 |
| Baricitinib | mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) | Open label RCT | NCT04390464 |
| Ruxolitinib | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | Double-blinded placebo-controlled RCT | NCT04377620 |
| Ruxolitinib | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | Double-blinded placebo-controlled RCT | NCT04362137 |
| Ruxolitinib | Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection (RUXO-COVID) | Double-blinded placebo-controlled RCT | NCT04477993 |
Abbreviations: JAK, Janus kinase; RCT, randomized controlled trial; ICU, intensive care unit.